Pharmacology of interleukin-1-induced neutrophil migration.
Neutrophil (PMN) accumulation induced by interleukin-1 beta (IL-1 beta, 5-20 ng) into the mouse air pouch was inhibited in a dose-dependent manner (2-200 micrograms) by concomitant injection of IL-1 receptor antagonist (IL-1RA). Similarly, co-administration of the neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) resulted in a reduction of the number of migrated PMN but only at the highest dose tested (200 micrograms). Although IL-1RA does not select between the two types of receptors so far described for IL-1, the effectiveness of alpha-MSH suggests that this property of the cytokine may occur through IL-1 type I receptor. This observation was confirmed by using a specific monoclonal antibody (mAb) raised against this receptor type, and which strongly inhibited (87%) IL-1-induced PMN recruitment.
Perretti
M
M
Department of Biochemical Pharmacology, William Harvey Research Institute, Medical College of Saint Bartholomew's Hospital, London, England.
Appleton
I
I
Parente
L
L
Flower
R J
RJ
D000818:Animals; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009504:Neutrophils / Q000187:drug effects*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology; D012795:Sialoglycoproteins / Q000494:pharmacology; D000521:alpha-MSH / Q000494:pharmacology
C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D000521:alpha-MSH